Pre-existing antibody-mediated adverse effects prevent the clinical development of a bacterial anti-inflammatory protein

Pre-existing antibody-mediated adverse effects prevent the clinical development of a bacterial anti-inflammatory protein

Bacterial pathogens have evolved to secrete strong anti-inflammatory proteins that target the immune system. It was long speculated whether these virulence factors could serve as therapeutics in diseases in which abnormal immune activation plays a role. We adopted the secreted chemotaxis inhibitory...

Full description

Bibliographic Details
Main Authors: Angelino T. Tromp, Yuxi Zhao, Ilse Jongerius, Erik C. J. M. Heezius, Pauline Abrial, Maartje Ruyken, Jos A. G. van Strijp, Carla J. C. de Haas, András N. Spaan, Kok P. M. van Kessel, Thomas Henry, Pieter-Jan A. Haas
Format: Article
Language:English
Published: The Company of Biologists 2020-09-01
Series:Disease Models & Mechanisms
Subjects:
c5ar chemotaxis
chips
clinical trials
humanized mouse
immune complex
Online Access:http://dmm.biologists.org/content/13/9/dmm045534

Internet

http://dmm.biologists.org/content/13/9/dmm045534

Similar Items